On October 27, 2021 Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, reported that the Company will host a virtual event on Thursday, November 4, 2021 at 11:00 AM ET to provide an update on the progress for its clinical pipeline (Press release, Precigen, OCT 27, 2021, View Source [SID1234592124]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The event will showcase data from several of the Company’s most advanced clinical programs, such as PRGN-3005 UltraCAR-T, PRGN-3006 UltraCAR-T, PRGN-2009 OTS AdenoVerse Immunotherapy and PRGN-2012 OTS AdenoVerse Immunotherapy. Precigen executives and key opinion leaders will participate in the event, including:
Helen Sabzevari, PhD, President and CEO of Precigen
Mary L. (Nora) Disis, MD, University of Washington (UW) Professor of Medicine, Director of UW Center for Translational Medicine, Professor in the Clinical Research Division at Fred Hutch and a lead investigator for the PRGN-3005 clinical study
David Sallman, MD, Assistant Member in the Department of Malignant Hematology at the H. Lee Moffitt Cancer Center & Research Institute and a lead investigator for the PRGN-3006 clinical study
James L. Gulley, MD, PhD, Branch Chief and Director of the Medical Oncology Service at the National Institutes of Health (NIH) and a lead investigator for the PRGN-2009 clinical study
Clint T. Allen, MD, Principal Investigator with the Section on Translational Tumor Immunology at the NIH and a lead investigator for the PRGN-2012 clinical study
Participants may register and access the live webcast through Precigen’s investor relations website in the Press & Events section. An archived recording will be posted to the investor relations website following the event.